Read by QxMD icon Read

linfoma de hodgkin

Tatiane Fernandes Farias, Karina da Silva Aguiar, Inajara Rotta, Klezia Morais da Silva Belletti, Juliane Carlotto
Objective: To implement a clinical pharmacy service focused on the comprehensive review of antineoplastic drugs used in therapy of hematological diseases. Methods: An interventional study was conducted in a Brazilian tertiary teaching hospital in two different periods, with and without a clinical pharmacy service, respectively. This service consisted of an antineoplastic prescription validation (analysis of patients' characteristics, laboratory tests, compliance with the therapeutic protocol and with pharmacotechnical parameters)...
July 2016: Einstein
Lidia Maroñas-Jiménez, Sara Burillo-Martínez, Fátima Tous-Romero, Jose Luis Rodríguez-Peralto, Javier Ortiz de Frutos, Pablo Luis Ortiz-Romero
The growing use of anti-TNF drugs during the last years has reopened the discussion about the possible increased risk of developing non-Hodgkin lymphoma in patients with such type of treatments. We present our clinical experience and critical opinion about the current situation of such issue regarding cutaneous T-cell lymphomas.El creciente uso de fármacos anti-TNF durante los últimos años ha reabierto el debate sobre el posible aumento de riesgo de linfomas no Hodgkin en los pacientes con este tipo de tratamientos...
2016: Dermatology Online Journal
Lidiane Miotto Barretta, Lúcia Marinilza Beccaria, Cláudia Bernardi Cesarino, Maria Helena Pinto
OBJECTIVE: to identify the model, average length of stay on site and complications of central venous catheter in patients undergoing transplant of hematopoietic stem cells and verify the corresponding relationship between the variables: age, gender, medical diagnosis, type of transplant, implanted catheter and insertion site. METHOD: a retrospective and quantitative study with a sample of 188 patients transplanted records between 2007 and 2011. RESULTS: the majority of patients used Hickman catheter with an average length of stay on site of 47...
June 7, 2016: Revista Latino-americana de Enfermagem
Anna Sureda, Carme Canals, Reyes Arranz, Dolores Caballero, Josep Maria Ribera, Mats Brune, Jacob Passweg, Rodrigo Martino, David Valcárcel, Joan Besalduch, Rafael Duarte, Angel León, Maria Jesus Pascual, Ana García-Noblejas, Lucia López Corral, Bianca Xicoy, Jordi Sierra, Norbert Schmitz
BACKGROUND: Although Hodgkin's lymphoma is a highly curable disease with modern chemotherapy protocols, some patients are primary refractory or relapse after first-line chemotherapy or even after high-dose therapy and autologous stem cell transplantation. We investigated the potential role of allogeneic stem cell transplantation in this setting. DESIGN AND METHODS: In this phase II study 92 patients with relapsed Hodgkin's lymphoma and an HLA-identical sibling, a matched unrelated donor or a one antigen mismatched, unrelated donor were treated with salvage chemotherapy followed by reduced intensity allogeneic transplantation...
February 2012: Haematologica
Pilar Miralles, Juan Berenguer, Josep-Maria Ribera
With the widespread use of highly active antiretroviral therapy (HAART) the incidence of systemic non-Hodgkin lymphoma (NHL) in patients infected with the Human Immunodeficiency Virus (HIV) has declined. HAART has also modified the clinical manifestations of these tumors, with a lower frequency of involvement of the central nervous system (CNS). Currently, the frequency of meningeal involvement at the time of diagnosis of NHL in HIV-infected patients varies between 3% and 5%. These figures are similar to those observed among immunocompetent hosts...
September 18, 2010: Medicina Clínica
Reyes Arranz, Eulogio Conde, Carlos Grande, Maria Victoria Mateos, Marco Gandarillas, Carmen Albo, Juan J Lahuerta, José M Fernández-Rañada, Miguel T Hernández, Natalia Alonso, José A García Vela, Sebastián Garzón, José Rodríguez, Dolores Caballero et al.
OBJECTIVES: The role of high-dose therapy and autologous stem-cell transplantation (HDT/ASCT) in the up-front treatment of poor-risk aggressive lymphoma is still unknown. We conducted a prospective multi-centre trial with dose-escalated CHOP (MegaCHOP) and tailored intensification prior to HDT/ASCT according to early response assessed by CT and gallium scan (Ga67S). PATIENTS AND METHODS: Eighty-six patients with newly diagnosed and Ga-67 avid aggressive B-cell lymphoma received MegaCHOP for three courses and were evaluated for response by CT and Ga67S...
March 2008: European Journal of Haematology
A Sureda, M Constans, A Iriondo, R Arranz, M D Caballero, M J Vidal, J Petit, A López, J J Lahuerta, E Carreras, J García-Conde, J García-Laraña, R Cabrera, I Jarque, D Carrera, J C García-Ruiz, M J Pascual, J Rifón, J M Moraleda, K Pérez-Equiza, C Albó, J Díaz-Mediavilla, A Torres, P Torres, J Besalduch, J Marín, M V Mateos, J M Fernández-Rañada, J Sierra, E Conde
PURPOSE: To analyse outcome and prognostic factors for overall survival (OS) and time to treatment failure (TTF) in 357 patients with Hodgkin's lymphoma (HL) undergoing an autologous stem cell transplantation (ASCT) after a first relapse and reported to the The Grupo Espanol de Linfomas/Trasplante Autologo de Medula Osea (GEL/TAMO) Cooperative Group. METHODS: Two hundred and twenty males and 137 females with a median age of 29 years were autografted in second remission (n=181), first sensitive relapse (n=148) and first resistant relapse (n=28)...
April 2005: Annals of Oncology: Official Journal of the European Society for Medical Oncology
J Rodríguez, M D Caballero, A Gutiérrez, J Marín, J J Lahuerta, A Sureda, E Carreras, A León, R Arranz, A Fernández de Sevilla, J Zuazu, J García-Laraña, J Rifon, R Varela, M Gandarillas, J SanMiguel, E Conde
BACKGROUND: T-cell immunophenotype constitutes an unfavorable prognostic factor in aggressive non-Hodgkin's lymphomas. High-dose chemotherapy with autologous stem-cell rescue (HDC/ASCT) is the best salvage therapy for patients with aggressive B-cell lymphomas. However, results with this therapy in peripheral T-cell lymphoma (PTCL) are not well defined. PATIENTS AND METHODS: From January 1990 to December 1999, 115 patients with PTCL underwent HDC/ASCT inside the Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO) registry...
December 2003: Annals of Oncology: Official Journal of the European Society for Medical Oncology
M Constans, A Sureda, M J Terol, R Arranz, M D Caballero, A Iriondo, I Jarque, E Carreras, J M Moraleda, D Carrera, A León, A López, C Albó, J Díaz-Mediavilla, P Fernández-Abellán, J C García-Ruiz, F Hernández-Navarro, R Mataix, J Petit, M J Pascual, J Rifón, J García-Conde, J M Fernández-Rañada, M V Mateos, J Sierra, E Conde
BACKGROUND: Patients with primary refractory Hodgkin's disease (PR-HD) have a dismal prognosis when treated with conventional salvage chemotherapy. We analyzed time to treatment failure (TTF), overall survival (OS) and clinical variables influencing the outcome in patients undergoing autologous stem cell transplantation (ASCT) for PR-HD and reported to the Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO). PATIENTS AND METHODS: Sixty-two patients, 41 males and 21 females with a median age of 27 years (range 13-55) were analyzed...
May 2003: Annals of Oncology: Official Journal of the European Society for Medical Oncology
A Sureda, R Arranz, A Iriondo, E Carreras, J J Lahuerta, J García-Conde, I Jarque, M D Caballero, C Ferrà, A López, J García-Laraña, R Cabrera, D Carrera, M D Ruiz-Romero, A León, J Rifón, J Díaz-Mediavilla, R Mataix, M Morey, J M Moraleda, A Altés, A López-Guillermo, J de la Serna, J M Fernández-Rañada, J Sierra, E Conde et al.
PURPOSE: To analyze clinical outcome and significant prognostic factors for overall (OS) and time to treatment failure (TTF) in a group of 494 patients with Hodgkin's disease (HD) undergoing autologous stem-cell transplantation (ASCT). PATIENTS AND METHODS: Detailed records from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group Database on 494 HD patients who received an ASCT between January 1984 and May 1998 were reviewed...
March 1, 2001: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
J L Hernández Hernández, J M Olmos Martínez, J Figols Ladrón de Guevara, J A Riancho Moral, J González Macías
Hypercalcemia associated with haematological neoplasms account for 15 to 20% of hipercalcemia in malignancy, and occurs usually in patients with multiple myeloma. However, its incidence in patients with linfoma is low, and it is observed usually in T-cell linfomas. Bone affectation is also uncommon in patients with non-Hodgkin linfoma. It usually is seen as a late manifestation of the disease, and its occurrence as the form of presentation is exceptional. We hereby report a patient with a B-cell non-Hodgkin linfoma presenting with hypercalcemia and femoral osteolytic lesions...
May 2000: Anales de Medicina Interna: Organo Oficial de la Sociedad Española de Medicina Interna
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"